 Galectin Therapeutics Inc NASDAQ: GALT has announced top-line clinical data from the extension cohort of Phase 1b trial of Belapectin in combination with Merck Co Incs NYSE: MRK Keytruda pembrolizumab in patients with metastatic melanoma and head neck cancer. The extension study enrolled heavily-pretreated nine melanoma patients and five head neck squamous cell carcinoma cancer patients. 